Products

iCAS-LV
HighRAD
Oncology AI
HighRAD's iCAS-LV™ is an FDA-cleared AI imaging platform for quantitative volumetric changes analysis of liver lesions, designed to accelerate oncology reporting and track disease progression through automated detection, segmentation, and RECIST 1.1 documentation.

See all 1 product →

About HighRAD

HighRAD is a healthcare AI company that has developed an innovative, FDA-cleared oncology AI imaging platform. This platform is specifically designed to advance oncology care by meticulously tracking disease progression throughout the entire patient journey through longitudinal, multi-organ analysis. It provides fully automated, quantitative, and comparative analysis for the accurate evaluation of disease progression and treatment efficacy.

For physicians, HighRAD’s technology offers significant advantages by enabling deeper disease insights, supporting more confident clinical decisions, and improving treatment planning. The platform integrates quantitative imaging analysis, automated lesion measurement, and standardized reporting into existing workflows. Its seamless connectivity allows integration with all CT, MRI, and PET systems, adapting to various clinical protocols. The technical foundation lies in its proprietary Simultaneous Deep Learning technology (SimU-Net) and multi-channel anisotropic 3D U-Net classification, which facilitates unparalleled lesion change detection and segmentation, ultimately enhancing disease understanding and boosting radiologist productivity for quicker, more confident diagnoses.

Focus Areas

Oncology AI imaging longitudinal quantitative analysis automatic lesion detection & segmentation volumetric measurements personalized treatment planning support pharmaceutical tool streamlining imaging workflow processes improving clinical outcomes liver lesion analysis (iCAS-LV) pulmonary metastases analysis (iCAS-LG) brain lesion analysis (iCAS-BR)

Business Intelligence

Key InvestorsIntegra Holdings, Quark Venture, 20/20 HealthCare Partners (2020 HCP), Hadasit, Yissum
TechnologyProprietary Simultaneous Deep Learning technology (SimU-Net), multi-channel anisotropic 3D U-Net classification, Region of Difference™ (ROD™) generic platform, seamless integration with CT, MRI, and PET systems
FDA Clearances1 cleared products (estimated)

What Physicians Need to Know

Oncology AI Imaging & Analysis
HighRAD specializes in advanced AI-driven imaging for oncology, offering comprehensive tools for automatic lesion detection, segmentation, and volumetric measurements across various anatomical sites.
Longitudinal Quantitative Analysis
The platform provides robust capabilities for longitudinal quantitative analysis, allowing physicians to precisely track disease progression and treatment response over time with objective metrics.
Personalized Treatment Planning Support
HighRAD's solutions aid in personalized treatment planning by providing detailed quantitative insights and analytical support, helping tailor therapies to individual patient needs.
Disease-Specific Modules (iCAS Series)
Featuring specialized modules like iCAS-LV (liver lesions), iCAS-LG (pulmonary metastases), and iCAS-BR (brain lesions), HighRAD offers targeted, high-precision analysis for critical oncological sites.
Workflow Streamlining & Outcomes Improvement
The company focuses on streamlining imaging workflow processes to enhance efficiency and consistency, ultimately contributing to improved clinical outcomes for patients.
Pharmaceutical Research Tool
HighRAD's advanced analytical capabilities also serve as a valuable tool for pharmaceutical companies, supporting drug development, clinical trials, and quantitative biomarker analysis.
Physician Tip

HighRAD stands out for physicians by offering a comprehensive, AI-powered suite that significantly enhances diagnostic accuracy and efficiency. Its automatic lesion detection and segmentation reduce inter-reader variability and save valuable time. The longitudinal quantitative analysis provides objective, data-driven insights crucial for monitoring treatment efficacy and disease progression, enabling more informed clinical decisions. The specialized iCAS modules (Liver, Lung, Brain) offer tailored, high-precision analysis for common metastatic sites, directly addressing specific clinical challenges. By streamlining imaging workflows and supporting personalized treatment planning, HighRAD empowers physicians to deliver more precise, efficient, and ultimately, better patient care.

The provided information does not explicitly detail specific integration partners or methods (e.g., PACS, EMR, vendor-neutral archives). However, given its role in streamlining imaging workflows, it is highly probable that HighRAD solutions are designed for seamless integration within existing clinical IT infrastructures to maximize utility and accessibility.

Products by HighRAD

1 product in the directory

iCAS-LV
HighRAD
Oncology AI
HighRAD's iCAS-LV™ is an FDA-cleared AI imaging platform for quantitative volumetric changes analysis of liver lesions, designed to accelerate oncology reporting and track disease progression through automated detection, segmentation, and RECIST 1.1 documentation.

What the Web Says

HighRAD (HighRadius) offers AI-driven solutions for the Office of the CFO, focusing on automating accounts receivable, treasury, and record-to-report processes. Users generally praise its automation capabilities, efficiency in cash application and collections, and seamless integration with ERP systems. However, employer reviews indicate significant concerns regarding work-life balance, management, and support responsiveness.

Overall: Mixed

Strengths

  • Robust AI automation for tasks like cash application, collections, and deductions.
  • Improved predictive analytics and intelligent automation for customer payment behavior.
  • Centralized dashboards and real-time reporting for better cash flow visibility.
  • Seamless integration with ERP systems.
  • Significant improvement in team efficiency and reduction in days sales outstanding (DSO).
  • Good learning experience and competitive work environment for some employees.

Limitations

  • Poor work-life balance and expectation of 24/7 availability for employees.
  • Toxic management and frequent changes in organizational structure.
  • Issues with pay and benefits, including lack of overtime compensation and limited promotion opportunities.
  • Inefficient customer service and support responsiveness, with frustrating ticket processes.
  • System can be slow with large amounts of data, and implementation/customization can be time-consuming.
  • Complex cases may still require manual handling.

Based on reviews from: Indeed.com, G2.com, Gartner Peer Insights, Stuut, Reddit

Last updated: 2026-07-19

Videos

News, demos, and interviews about HighRAD.

Loading videos...

Videos load interactively. If none appear, search YouTube for HighRAD →

View all on YouTube

Press & Coverage

HighRAD
HighRAD | Revolutionizing Oncology Care
HighRAD's Oncology AI imaging platform is designed to track the entire patient journey, offering profound insights into disease progression through advanced quantitative, multi-organ analysis. Their cutting-edge technology enhances disease understanding, improves treatment outcomes, and boosts radiologist productivity.
unknown
HighRAD
Technology - HighRAD
HighRAD's system offers seamless connectivity, integrating with all CT, MRI, and PET systems, and is adaptable to various clinical protocols. Its technical prowess is grounded in proprietary Simultaneous Deep Learning technology (SimU-Net) and multi-channel anisotropic 3D U-Net classification, enabling unparalleled lesion change detection and segmentation.
unknown
HighRAD
About - HighRAD
HighRAD provides an innovative FDA cleared oncology AI imaging platform for a range of clinical applications, delivering fully automated, quantitative, and comparative analysis for accurate evaluation of disease progression and treatment efficacy. The company's leadership team includes Prof. Leo Joskowicz (Co-Founder & CTO) and Prof. Jacob Sosna (Co-Founder, CMO & Chairman, SAB).
unknown
accessdata.fda.gov
K231690 - accessdata.fda.gov
On March 1, 2024, the FDA reviewed HighRAD Ltd.'s 510(k) premarket notification and determined the device is substantially equivalent to legally marketed predicate devices. The device is subject to general controls provisions of the Act, including requirements for annual registration, device listing, good manufacturing practice, and labeling.
2024-03

Frequently Asked Questions

HighRAD's AI platform revolutionizes oncology care by providing advanced quantitative, multi-organ analysis, including automatic lesion detection, segmentation, and accurate volumetric measurements. This comprehensive data supports physicians in personalized treatment planning by offering profound insights into disease progression and optimizing treatment strategies.
HighRAD offers specialized iCAS modules for various anatomical regions, including iCAS-LV for liver lesion analysis, iCAS-LG for pulmonary metastases analysis, and iCAS-BR for brain lesion analysis. These modules are designed to provide automated quantitative volumetric change analysis for radiological follow-up of longitudinal scans.
Yes, HighRAD's platform is specifically designed for AI-powered longitudinal quantitative analysis, enabling comprehensive tracking of the entire patient journey and disease progression. This capability allows for the comparative measurement of lesions over time, enhancing the understanding of treatment outcomes.
HighRAD's technology serves as a pharmaceutical tool by offering AI assistance for quantitative comparative measurement to evaluate treatment or drug responses and track clinical studies. This provides standardized and reproducible imaging biomarkers, which can accelerate drug development and improve the efficiency of clinical trials.
HighRAD's iCAS-LV device has received FDA 510(k) clearance, classifying it as a Class II medical device for medical image management and processing. While specific details on other clearances or data privacy protocols like HIPAA/GDPR are not explicitly detailed in the provided snippets, medical device companies typically adhere to stringent regulatory and data security standards.
HighRAD's pricing model is not publicly disclosed, but similar to other enterprise SaaS solutions in the healthcare AI space, it likely operates on a subscription-based model. Factors influencing the total cost of ownership would typically include the specific modules chosen, integration requirements, and the scale of deployment within a healthcare facility.
HighRAD emphasizes seamless connectivity and easy integration with existing CT, MRI, and PET systems, adaptable to various clinical protocols. While specific details on training programs are not provided, the company's focus on streamlining imaging workflow processes and improving clinical outcomes implies comprehensive support for effective platform utilization.

Related Companies

QuickIntell is an AI-first healthcare technology company dedicated to transforming healthcare operations for physicians and healthcare providers. The company leverages advanced AI agents, including Computer Vision, Machine Learning, Optical Character Recognition (OCR), and Natural Language Processing (NLP), to streamline administrative workflows and enhance Revenue Cycle Management (RCM). QuickIntell’s solutions are designed to reduce administrative burden, […]

Ease Tax Relief, founded in 2016, is a tax relief and resolution company based in Harleysville, PA. The company specializes in helping individuals and small businesses resolve issues with the IRS, offering services such as Offer in Compromise, Partial Pay Installment Agreements, Payment Plans, and Penalty Reduction. Owned and operated by Zheng Yang, a CPA […]

CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]

Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]

OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]

Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.